Author

Karthik Murugan

Integrated DNA Technologies (United States)ORCID 0000-0002-1743-3713Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genomics· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:perturbation response prediction· 1 Approach:statistical model· 1 Research Focus:variant calling· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

Garrett R. RettigiD· 2 shared Gavin KurganiD· 2 shared M. Kyle CromeriD· 2 shared Mark A. BehlkeiD· 2 shared Andrea Sánchez PeñaiD· 1 shared Ashley M. JacobiiD· 1 shared Bernice Thommandru· 1 shared Christopher A. VakulskasiD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Garrett R. RettigORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologyNature CommunicationsPeer-reviewedAug 11, 2026

UNCOVERseq Enables Sensitive and Controlled Gene Editing Off-Target Nomination Across CRISPR-Cas Modalities and Systems

Kyle J. Kinney, Kun Jia, He Zhang…·Gavin Kurgan

UNCOVERseq is a workflow for sensitive off-target nomination in CRISPR-Cas editing, demonstrating superior performance across multiple modalities and systems.

5 citationstop 3%

humanCRISPR screen

𝕏 PostBluesky

GenomicsMolecular TherapyPeer-reviewedFeb 15, 2023

Comparative analysis of CRISPR off-target activity discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells

M. Kyle Cromer, Kiran R. Majeti, Garrett R. Rettig…·Matthew Hebden Porteus

This study compares CRISPR off-target detection tools using ex vivo edited CD34+ HSPCs, finding that HiFi Cas9 reduces off-target sites and some methods outperform others in sensitivity and specificity.

42 citationstop 5%

humanCRISPR screen

𝕏 PostBluesky